LUBT010 (ranibizumab biosimilar) / Lupin - LARVOL DELTA

...new medicines recommended for approval (European Medicines Agency) - "Ranluspec (ranibizumab), for the treatment of neovascular age-related macular degeneration, visual impairment and other retinopathies."

CHMP • Diabetic Macular Edema • Diabetic Retinopathy • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD (clinicaltrials.gov) - P3 | N=600 | Completed | Sponsor: Lupin Ltd. | Recruiting ➔ Completed | Trial completion date: Oct 2022 ➔ May 2024 | Trial primary completion date: Oct 2022 ➔ May 2024

Trial completion • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration